Table 1 Descriptive Analysis of demographic and clinical data
From: Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
Parameter (N) | Categories | Frequency (%) |
|---|---|---|
Gender (258) | Female | 65.1% |
Male | 34.9% | |
Comorbidities (258) | Present | 12.4% |
Absent | 87.6% | |
Disease duration (258) | <  5 years | 35.7% |
5–10 years | 29.4% | |
>  10 years | 34.9% | |
Walking disability (258) | Fully ambulatory, self-sufficient, which represents EDSS 0–3 | 46.8% |
Ambulatory for 500 m without aid/rest which represents EDSS 4–4.5 | 16.3% | |
Ambulatory for 200 m without aid/rest which represents EDSS 5 | 14.0% | |
Intermittent or unilateral constant assistance which represents EDSS 5.5–6 | 12.4% | |
Constant bilateral assistance (canes, crutches, or braces) which represents EDSS 6.5 | 6.2% | |
restricted to wheelchair which represents EDSS 7 | 4.3% | |
Total Number of Rituximab injections (258) | Once | 7.8% |
Twice | 16.3% | |
3 times | 14.7% | |
>  4 times | 61.2% | |
Extended interval dosing (258) | Yes | 28.7% |
No | 71.3% | |
Relapse during the pandemic (258) | Yes | 16.3% |
No | 83.7% | |
Relapse management (42) | Outpatient | 35.7% |
Inpatient | 9.6% | |
Not treated | 54.7% | |
Recent corticosteroid use (42) | Yes | 14.3% |
No | 85.71% | |
self-isolation (258) | Yes | 87.2% |
No | 12.8% | |
Contact with COVID-19 Patients (258) | Yes | 4.3% |
Not Aware | 95.7% | |
Suspected Covid-19 infection (258) | Yes | 9.7% |
No | 90.3% | |
Assessment of Covid-19 (RT-PCR or Imaging) (258) | Performed | 8.5% |
Not performed | 91.5% |